Get the Stockscreener App
0.854
4.15%
0.034
Pre-market:
.82
-0.034
-3.98%
Clearmind Medicine Inc stock is traded at $0.854, with a volume of 4.20M.
It is up +4.15% in the last 24 hours and up +29.39% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$0.82
Open:
$0.75
24h Volume:
4.20M
Relative Volume:
0.96
Market Cap:
$2.05M
Revenue:
-
Net Income/Loss:
$-8.44M
P/E Ratio:
-5.4849
EPS:
-0.1557
Net Cash Flow:
$-4.41M
1W Performance:
+31.38%
1M Performance:
+29.39%
6M Performance:
-97.87%
1Y Performance:
-97.87%
1-Day Range:
$0.715
$0.90
1-Week Range:
$0.5855
$1.52
52-Week Range:
$0.5855
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.854 | 1.96M | 0 | -8.44M | -4.41M | -0.1557 |
VRTX
Vertex Pharmaceuticals Inc
|
437.67 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.58 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.22 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.58 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.41 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN
Why Is Clearmind Medicine Stock Sliding On Wednesday? - Benzinga
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings - Sahm
Clearmind Medicine (NASDAQ: CMND) adds $2.7M notes and converts $2.68M to shares - Stock Titan
Clearmind’s CMND-100 meets primary endpoint in phase I/IIa trial - Investing.com India
Clearmind Medicine (CMND) issues $2.7M in new convertible promissory notes at 90% of principal - Stock Titan
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care - The Manila Times
[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer) | CMND SEC FilingForm 6-K - Stock Titan
Clearmind Medicine (CMND) Stock Surges 100% After Drug Trial Hit Safety Goals - MEXC
Trump order spotlights psychedelic drugs for veterans, Clearmind says - Stock Titan
CMND Stock Jumps As Psychedelic Tailwinds Lift Clearmind - StocksToTrade
Clearmind Medicine jumps 64.7% after CMND-100 hits key safety endpoint in early AUD study - Quiver Quantitative
Clearmind Medicine's CMND-100 Achieves Key Safety Milestone in Alcohol Use Disorder Trial: What U.S. - AD HOC NEWS
Clearmind Medicine Says Drug Candidate Met Primary Endpoint in Phase I/IIa Trial to Treat Alcohol Use Disorder - Moomoo
Clearmind Medicine (CMND) Stock Doubles as CMND-100 Passes Critical Safety Milestone - Blockonomi
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results - Benzinga
Why Is Clearmind Stock Rising Monday?Clearmind Medicine (NASDAQ:CMND) - Benzinga
Clearmind Medicine CMND Stock Jumps On Psychedelic Policy Tailwinds - timothysykes.com
$Clearmind Medicine (CMND.US)$ im out - Moomoo
Clearmind Medicine Inc. Announces Successful Phase I/IIa Trial Results for Non-Hallucinogenic CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Alcohol use disorder drug clears safety test even at higher dose - Stock Titan
CMND Stock Set For Biggest Intraday Gains In Over Three Years — Here’s Why Retail Is Eyeing Further Upside - Stocktwits
Clearmind (CMND) Stock: Sell Signals (On the Radar) 2026-04-18Earnings Beat Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Clearmind (CMND) Stock Exits Position (Rockets) 2026-04-16Risk Reward Ratio - Cổng thông tin điện tử Tỉnh Sơn La
symbol__ Stock Quote Price and Forecast - CNN
CMND Forecast, Price Target & Analyst Ratings | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Clearmind gets safety board nod to continue alcohol disorder trial By Investing.com - Investing.com Australia
Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Positive DSMB backs Clearmind (Nasdaq: CMND) CMND-100 AUD trial - Stock Titan
Clearmind gets safety board nod to continue alcohol disorder trial - Investing.com
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial - The Manila Times
Alcohol disorder drug advances after no serious adverse events - Stock Titan
Clearmind Medicine (CMND) converts $875K notes at $0.60 and amends floor - Stock Titan
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Clearmind Medicine (CMND) raises $1.58M cash via $1.75M notes - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Crude Oil Falls Sharply; Wells Fargo Earnings Miss ViewsAvanos Medical (NYSE:AVNS), Clearmind Medicine - Benzinga
Clearmind’s CMND-100 meets primary endpoint in phase I/IIa trial By Investing.com - Investing.com South Africa
Clearmind Medicine stock surges on phase trial results By Investing.com - Investing.com South Africa
Clearmind (Nasdaq: CMND) CMND-100 meets key safety goal in AUD trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - Bitget
Clearmind Medicine Inc. Reports Positive Phase I/IIa Trial Results for CMND-100 in Treating Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - The Manila Times
Clearmind Medicine stock surges on phase trial results - Investing.com
Alcohol use disorder drug clears early safety test at higher dose - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):